Reyes Bernabé
YOU?
Author Swipe
View article: Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC): 2nd Spanish Lung Cancer Group (GECP) expert consensus statement
Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC): 2nd Spanish Lung Cancer Group (GECP) expert consensus statement Open
Updated suggestions were developed for the most relevant situations in the treatment of patients with early-stage and locally advanced NSCLC. These suggestions will support clinical decision-making in daily practice. This paper presents th…
View article: Incidence of second primary cancers in lung cancer survivors by oncological treatment: a nationwide prospective cohort study in Spain
Incidence of second primary cancers in lung cancer survivors by oncological treatment: a nationwide prospective cohort study in Spain Open
View article: Supplementary table S4 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Supplementary table S4 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy Open
Table S4: Differentially expressed genes between High and Low Top 1% clonal space tumors.
View article: Figure S1 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Figure S1 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy Open
PFS and OS survival stratified by pre-treatment evenness, TMB, and PD-L1. Correlation between tissue evenness and TMB or PD-L1. Mutations and pre-treatment tissue top 1% clonal space.
View article: Figure S2 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Figure S2 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy Open
Tissue TCR evenness and top 1% clonal space are independent of reported read counts, clones identified, and tissue origing.
View article: Supplementary file S1 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Supplementary file S1 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy Open
TCR Clone lists identified in pre-treatment samples
View article: Supplementary table S1, S2, and S3 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Supplementary table S1, S2, and S3 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy Open
Table S1: Patients' samples and techniques. Table S2: Summary of available samples. Table S3: Canonical somatic tumor mutations and top 1%.
View article: Supplementary file S2 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Supplementary file S2 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy Open
TCR Clone lists identified in post-treatment samples
View article: Figure S3 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Figure S3 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy Open
Stability of evenness and top 1% across technical replicates and Clonal reproducibility
View article: Data from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Data from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy Open
Purpose:Characterization of the T-cell receptor (TCR) repertoire may be a promising source for predictive biomarkers of pathologic response to immunotherapy in locally advanced non–small cell lung cancer (NSCLC).Experimental Design:In this…
View article: Supplementary table S5 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Supplementary table S5 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy Open
Table S5: Gene Ontology enrichment analysis of differentially expressed genes between High and Low Top 1% clonal space tumors.
View article: Figure S4 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Figure S4 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy Open
Clonal space occupied by shared or newly emergent clones top 1% post-T clones in PBMCs at pre- and post-treatment timepoints.
View article: Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysis
Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysis Open
LB with F1L CDx test is a cost-effective strategy in Spain for patients with advanced NSCLC without tissue sample available for molecular diagnosis, improving the personalized treatment of these patients.
View article: Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis Open
View article: Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer
Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer Open
View article: BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC
BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC Open
View article: HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer
HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer Open
An in-depth exploration of the functions of HMGB1 mRNA and protein is expected to uncover new potential targets and provide a basis for treating metastatic NSCLC in combination with ICI.
View article: Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP
Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP Open
View article: Evaluación del proceso de extracción de aceite de girasol como alternativa en la producción de lubricantes industriales
Evaluación del proceso de extracción de aceite de girasol como alternativa en la producción de lubricantes industriales Open
La extracción de aceites es un proceso fundamental en la producción de una amplia variedad de aceites vegetales y animales que se utilizan en diversas industrias, como la alimentaria, cosmética, farmacéutica y otros sectores industriales. …
View article: Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry
Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry Open
View article: Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab
Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab Open
Survival beyond 2 years is rare in patients with extensive-stage small-cell lung cancer (ES-SCLC) treated with chemotherapy alone. We describe a patient with ES-SCLC who was treated with carboplatin, etoposide and the programmed death-liga…
View article: MA03.11 Big Data and Artificial Intelligence for Exploring the Role of Genetic Risk. Family History of Cancer and Lung Cancer. Results from CLARIFY
MA03.11 Big Data and Artificial Intelligence for Exploring the Role of Genetic Risk. Family History of Cancer and Lung Cancer. Results from CLARIFY Open
View article: P1.27-07 BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy
P1.27-07 BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy Open
View article: LBA61 Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable stage III NSCLC: Final analysis from PACIFIC-6
LBA61 Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable stage III NSCLC: Final analysis from PACIFIC-6 Open
View article: Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study
Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study Open
This TTR analysis describes the clinical reality surrounding the initial management and survival outcomes for stage III NSCLC in Spain and presents survival outcomes comparable with other real-world evidence. It provides insights into the …
View article: 1278P ORIGEN: Multicenter study on the prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain
1278P ORIGEN: Multicenter study on the prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain Open
View article: HEMANGIOSSARCOMA MUSCULAR EM CÃO – RELATO DE CASO
HEMANGIOSSARCOMA MUSCULAR EM CÃO – RELATO DE CASO Open
O hemangiossarcoma é uma neoplasia maligna comum em cães, pouco comum em felinos e que confere um prognóstico de reservado a ruim nos pacientes acometidos com a forma visceral, e favorável naqueles que desenvolvem a forma cutânea da doença…
View article: HEMANGIOSSARCOMA MUSCULAR EM CÃO – RELATO DE CASO
HEMANGIOSSARCOMA MUSCULAR EM CÃO – RELATO DE CASO Open
O hemangiossarcoma é uma neoplasia maligna comum em cães, pouco comum em felinos e que confere um prognóstico de reservado a ruim nos pacientes acometidos com a forma visceral, e favorável naqueles que desenvolvem a forma cutânea da doença…
View article: Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer
Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer Open
Lung cancer (LC) is associated with ageing, with the average age of affected individuals being approximately 70 years. However, despite a higher incidence and prevalence among older people, the older adult population is underrepresented in…
View article: PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement Open
Introduction: There are currently three first-line immunotherapy options used as monotherapy in advanced non-small cell lung cancer (NSCLC) patients with high programmed death ligand 1 (PD-L1) expression (≥50%). This manuscript aims to eva…